Enzyme-linked immunosorbent assay (ELISA) is an analytic biochemical assay that utilizes enzyme-linked antibodies on a microwell platform to quantitate specific proteins within biological samples. Visual detection is then achieved by adding the enzyme’s substrate, which causes a color-changing reaction to occur. There are three different types of ELISA that are most commonly used: indirect ELISA, sandwich ELISA and competitive ELISA. These assays are extremely useful for high-throughput diagnostic screenings drug testing.
Novus offers a range of support options for ELISA when you buy a product to help you with your ELISA experiment including:
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Biotin | NBP1-42761 | |||
| HRP | NBP1-42762 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB600-1131SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | PHSLB00D | |||
| Carrier Free | SSLB00D | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 488 | DDX0362A488-100 | |||
| Alexa Fluor 546 | DDX0362A546-100 | |||
| Alexa Fluor 647 | DDX0362A647-100 | |||
| Biotin | DDX0362B-100 | |||
![N/A IL-5 [Biotin]](http://images.novusbio.com/fullsize2/DATA_IL5_DY405_ELISA_2002.jpg "N/A IL-5 [Biotin]")
![N/A BDNF [Biotin]](http://images.novusbio.com/fullsize2/DATA_BDNF_DY248_ELISA_1837.jpg "N/A BDNF [Biotin]")
![N/A Creatinine [Biotin]](http://images.novusbio.com/fullsize2/DATA_Creatinine_KGE005_ELISA_907.jpg "N/A Creatinine [Biotin]")
![N/A Creatinine [Biotin]](http://images.novusbio.com/fullsize2/Creatinine_KGE005_ELISA_220.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - Staining of Human Liver (A) and Tonsil (B) with antibody at 0.001 ug/mL and Rat Brain lysate (C) with antibody at 0.3 ug/mL (35 ug protein in RIPA buffer). Detected by chemiluminescence. Approx. 37 kDa band observed in Rat Brain lysates and approx. 35 kDa in Human Liver and Tonsil lysates (calculated MW of 36.1 kDa according to Human NP_002037.2 and 35.8 kDa according to Rat NP_058704.1).](http://images.novusbio.com/fullsize/GAPDH-Antibody-Western-Blot-NB300-320-img0008.jpg "Western Blot: GAPDH Antibody [NB300-320] - Staining of Human Liver (A) and Tonsil (B) with antibody at 0.001 ug/mL and Rat Brain lysate (C) with antibody at 0.3 ug/mL (35 ug protein in RIPA buffer). Detected by chemiluminescence. Approx. 37 kDa band observed in Rat Brain lysates and approx. 35 kDa in Human Liver and Tonsil lysates (calculated MW of 36.1 kDa according to Human NP_002037.2 and 35.8 kDa according to Rat NP_058704.1).")
![Immunocytochemistry/Immunofluorescence: GAPDH Antibody [NB300-320] - Immunofluorescence analysis of paraformaldehyde fixed HeLa cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing cytoplasmic and vesicle staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL). Strong expression of the protein seen in the cytoplasm and vesicles of HeLa cells.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Immunocytochemistry-Immunofluorescence-NB300-320-img0010.jpg)
![Immunohistochemistry-Paraffin: GAPDH Antibody [NB300-320] - Staining of paraffin embedded Human Pancreas. Antibody at 2.5 ug/mL. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Immunohistochemistry-Paraffin-NB300-320-img0011.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - stai Mutants Have Reduced Levels of alpha-Tubulin, Acetylated alpha-Tubulin, and Kinesin Heavy Chain Protein. Representative western blots of total protein extracted from stai mutant third instar larvae. Heterozygous stai/+ mutant larvae exhibit mild reductions in the levels of alpha-tubulin and acetylated alpha-tubulin compared with wild type larvae. Homozygous stai mutant larvae have dramatic reductions in the levels of alpha-tubulin, acetylated alpha-tubulin and the heavy chain subunit of the microtubule motor protein kinesin compared to wildtype. Df(2L) BSC239 represents a second chromosomal deficiency that excludes the stai gene. GAPDH is used as a loading control. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0068324), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Western-Blot-NB300-320-img0005.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - Staining of HEK293 (A) and HeLa (B) cell lysate (35 ug protein in RIPA buffer). Antibody at 0.001 ug/mL. Detected by chemiluminescence. Approx 36 kDa band observed in lysates of cell line HEK293 and approx. 35 kDa in HeLa cell lysates.(calculated MW of 36.1 kDa according to Human NP_002037.2).](http://images.novusbio.com/fullsize/GAPDH-Antibody-Western-Blot-NB300-320-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: GAPDH Antibody [NB300-320] - Immunofluorescence analysis of paraformaldehyde fixed A549 cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing cytoplasmic and vesicle staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL). Strong expression of the protein seen in the cytoplasm and vesicles of A549 cells.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Immunocytochemistry-Immunofluorescence-NB300-320-img0009.jpg)
![Immunohistochemistry-Paraffin: GAPDH Antibody [NB300-320] - Upregulation of GAPDH and Tom20 in C6 gliomas. A small glioma labeled with antibodies against GAPDH. The brightness and contrast have been increased. Image collected and cropped by CiteAb from the following publication (//www.biomedcentral.com/1756-0500/8/207), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Immunohistochemistry-Paraffin-NB300-320-img0006.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - PAR2 causes contraction of smooth muscle cells from human prostate. (A & B) Decrease in diameter of collagen hydrogels after PAR2 activation with SLIGKV (80 µM). (C) Representative western blot & (D) densitometry showing time dependent increase in level of phosphorylated MLC20 in PSMC after PAR2 is activated. Data represent mean ± SEM of at least three independent experiments. Diameter of collagen hydrogels were measured in ImageJ (version 1.50i) & significance analyzed in Prism (version 7.04) with one‐way ANOVA followed by Tukey's multiple comparison test. *P < 0.05, **P < 0.01 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31198907), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-31020241534329.jpg)
![Immunocytochemistry/ Immunofluorescence: GAPDH Antibody [NB300-320] - Upregulation of GAPDH & Tom20 in C6 gliomas. a A section of rat brain stained with hematoxilin & eosin to show a glioma produced by implantation of C6 cells in the right caudate nucleus. In this case, cells also grew in the region of the syringe needle track through the cortex. (b–d). A small glioma labeled by bisbenzamide (b) & with antibodies against Tom20 (c) & GAPDH (d). The brightness & contrast have been increased. e Illustration of a strip perpendicular to the rim of a glioma (labeled with bisbenzamide) & along which intensity profiles were measured. f, g Tom20 & GAPDH fluorescence along such a strip (barely visible without enhancement). The graphs show the raw intensity values given by ImageJ. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26032618), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-310202415392578.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - CDC20B was the protein effector regulated by hsa-miR-633. (a) CDC20B level was up-regulated after ox-LDL treatment revealed by Western blotting. (b) CDC20B level was decreased after the treatment of hsa-miR-633 mimics revealed by Western blotting. (c) CDC20B level was increased after the treatment of hsa-miR-633 inhibitor revealed by Western blotting. (d) The luciferase reporter plasmids were constructed as illustrated. (e) Relative luciferase activities after co-transfection CDC20B WT & hsa-miR-633/Control, or CDC20B Mut & hsa-miR-633/Control were measured. (f) The expression levels of two proliferation markers, Ki67 & PCNA after the treatment of si-CDC20B were measured using Western blotting. (g) Colony formation assay was conducted to examine the proliferation abilityafter the treatment of si-CDC20B. (h) Transwell migration & invasion assays were conducted to examine the migration & invasion abilities of VSMCs after the treatment of si-CDC20B. (i) Quantification results of (g). (j) Quantification results of (h). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-310202416205177.jpg)
![Simple Western: GAPDH Antibody [NB300-320] - MiR-34a affects stroke outcomes via interacting with cytochrome c. (A) WES system image showing CYC, VDAC & GAPDH expression from hemispheres of WT & miR-34a−/− mice at 6 h post-stroke. (B) Relative CYC expression normalized to GAPDH from the data generated by the WES system. CYC level is significantly decreased in ischemic hemispheres of WT mice but no significant changes in miR-34a−/− mice between contralateral hemispheres (Control) & ischemic hemispheres (Ischemia). N = 5 per group, **p < 0.01, One-way ANOVA followed by post hoc Tuckey’s test was used for data analysis. Data are expressed as mean ± S.D. (C) Relative VDAC expression normalized to GAPDH from the data generated by the WES system. VDAC was not significantly altered in WT mice nor miR-34a−/− mice. (D) Multiplexed WES system image showing CYC & GAPDH expression from purified pCECs of WT & miR-34a−/− mice (n = 10 per group, pooled cell samples) at 6 h post-stroke. (E) Relative CYC expression by normalization to GAPDH. A 2.8 fold decrease of CYC level was observed in WT mice but no changes were observed in miR-34a−/− mice between contralateral hemispheres & ischemic hemispheres. (F) A CYC reporter was coexpressed with a miR-34a plasmid, a miR-34a mimic, a miR-34c mimic, or a plasmid control in cultured cerebral vascular endothelial cells for 24 hours. Relative firefly luciferase activity was evaluated & normalized to renilla luciferase activity. Relative firefly luciferase activity was reduced by miR-34a plasmid & miR-34a mimic. The experiment was repeated 3 times & triplicates were used for each analysis. Data represents the mean ± S.D. *p < 0.05. One-way ANOVA followed by post-hoc Tuckey’s test was used for analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32094435), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-3102024162180.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - Hsa-miR-633 inhibitor could reverse the si-circ_0008896 phenotypes. (a) CCK8 assay was conducted to measure cell viability after up-regulation of hsa-miR-633. (b) The expression levels of two proliferation markers, Ki67 & PCNA after up-regulation of hsa-miR-633 were measured using Western blotting. (c) CCK8 assay was conducted to measure cell viability after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (d) The expression levels of two proliferation markers, Ki67 & PCNA after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor were measured using Western blotting. (e) Colony formation assay was conducted to examine proliferation ability number of colonies after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (f) Quantification results of (e). (g) Transwell migration & invasion assays were conducted to examine the migration & invasion abilities of VSMCs after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (h) Quantification results of (g). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-31020241620373.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - Down-regulation of hsa_circ_0008896 inhibited proliferation, migration & invasion in vitro. (a) The expression level of hsa_circ_0008896 after si-circ_0008896 transfection was detected using quantitative PCR. (b) CCK8 assay was conducted to measure cell viability after down-regulation of hsa_circ_0008896. (c) The expression levels of two proliferation markers, Ki67 & PCNA after down-regulation of hsa_circ_0008896 were detected using Western blotting. (d) Colony formation assay was conducted to examine proliferation ability after down-regulation of hsa_circ_0008896. (e) The quantification results of (d). (f) Transwell migration & invasion assays were conducted to examine the migration & invasion abilities of VSMCs after down-regulation of hsa_circ_0008896. (g) The quantification results of (f). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-31020241621234.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - CDC20B was the protein effector regulated by hsa-miR-633. (a) CDC20B level was up-regulated after ox-LDL treatment revealed by Western blotting. (b) CDC20B level was decreased after the treatment of hsa-miR-633 mimics revealed by Western blotting. (c) CDC20B level was increased after the treatment of hsa-miR-633 inhibitor revealed by Western blotting. (d) The luciferase reporter plasmids were constructed as illustrated. (e) Relative luciferase activities after co-transfection CDC20B WT & hsa-miR-633/Control, or CDC20B Mut & hsa-miR-633/Control were measured. (f) The expression levels of two proliferation markers, Ki67 & PCNA after the treatment of si-CDC20B were measured using Western blotting. (g) Colony formation assay was conducted to examine the proliferation abilityafter the treatment of si-CDC20B. (h) Transwell migration & invasion assays were conducted to examine the migration & invasion abilities of VSMCs after the treatment of si-CDC20B. (i) Quantification results of (g). (j) Quantification results of (h). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-310202416205198.jpg)
![Simple Western: GAPDH Antibody [NB300-320] - MiR-34a affects stroke outcomes via interacting with cytochrome c. (A) WES system image showing CYC, VDAC & GAPDH expression from hemispheres of WT & miR-34a−/− mice at 6 h post-stroke. (B) Relative CYC expression normalized to GAPDH from the data generated by the WES system. CYC level is significantly decreased in ischemic hemispheres of WT mice but no significant changes in miR-34a−/− mice between contralateral hemispheres (Control) & ischemic hemispheres (Ischemia). N = 5 per group, **p < 0.01, One-way ANOVA followed by post hoc Tuckey’s test was used for data analysis. Data are expressed as mean ± S.D. (C) Relative VDAC expression normalized to GAPDH from the data generated by the WES system. VDAC was not significantly altered in WT mice nor miR-34a−/− mice. (D) Multiplexed WES system image showing CYC & GAPDH expression from purified pCECs of WT & miR-34a−/− mice (n = 10 per group, pooled cell samples) at 6 h post-stroke. (E) Relative CYC expression by normalization to GAPDH. A 2.8 fold decrease of CYC level was observed in WT mice but no changes were observed in miR-34a−/− mice between contralateral hemispheres & ischemic hemispheres. (F) A CYC reporter was coexpressed with a miR-34a plasmid, a miR-34a mimic, a miR-34c mimic, or a plasmid control in cultured cerebral vascular endothelial cells for 24 hours. Relative firefly luciferase activity was evaluated & normalized to renilla luciferase activity. Relative firefly luciferase activity was reduced by miR-34a plasmid & miR-34a mimic. The experiment was repeated 3 times & triplicates were used for each analysis. Data represents the mean ± S.D. *p < 0.05. One-way ANOVA followed by post-hoc Tuckey’s test was used for analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32094435), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-31020241621811.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - Hsa-miR-633 inhibitor could reverse the si-circ_0008896 phenotypes. (a) CCK8 assay was conducted to measure cell viability after up-regulation of hsa-miR-633. (b) The expression levels of two proliferation markers, Ki67 & PCNA after up-regulation of hsa-miR-633 were measured using Western blotting. (c) CCK8 assay was conducted to measure cell viability after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (d) The expression levels of two proliferation markers, Ki67 & PCNA after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor were measured using Western blotting. (e) Colony formation assay was conducted to examine proliferation ability number of colonies after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (f) Quantification results of (e). (g) Transwell migration & invasion assays were conducted to examine the migration & invasion abilities of VSMCs after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (h) Quantification results of (g). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-31020241621849.jpg)
![N/A TIM-1/KIM-1/HAVCR [HRP]](http://images.novusbio.com/fullsize2/TIM1_DSKM100_ELISA_1158.jpg "N/A TIM-1/KIM-1/HAVCR [HRP]")
![N/A TIM-1/KIM-1/HAVCR [HRP]](http://images.novusbio.com/fullsize2/TIM1_DSKM100_ELISA_1159.jpg)
![N/A Lipocalin-2/NGAL [HRP]](http://images.novusbio.com/fullsize2/DATA_Lipocalin2_DLCN20_ELISA_742.jpg "N/A Lipocalin-2/NGAL [HRP]")
![N/A Lipocalin-2/NGAL [HRP]](http://images.novusbio.com/fullsize2/Lipocalin-2_DLCN20_ELISA_131.jpg)
![Western Blot: IL-6 Antibody [NB600-1131] - Western Blot: IL-6 Antibody [HRP] [NBP1-42762] - Lane 1: Human IL-6. Lane 2: none. Load: 50 ng per lane. Primary antibody: none. Secondary antibody: Peroxidase Human IL-6 secondary antibody at 1:1,000 for 60 min at RT. Block: incubated with blocking buffer for 30 min at RT. Predicted/Observed size: 20 kDa for Human IL-6. Other band(s): none. Image using the HRP form of this antibody.](http://images.novusbio.com/fullsize/IL-6-Antibody-Western-Blot-NB600-1131-img0014.jpg "Western Blot: IL-6 Antibody [NB600-1131] - Western Blot: IL-6 Antibody [HRP] [NBP1-42762] - Lane 1: Human IL-6. Lane 2: none. Load: 50 ng per lane. Primary antibody: none. Secondary antibody: Peroxidase Human IL-6 secondary antibody at 1:1,000 for 60 min at RT. Block: incubated with blocking buffer for 30 min at RT. Predicted/Observed size: 20 kDa for Human IL-6. Other band(s): none. Image using the HRP form of this antibody.")
![Immunohistochemistry: IL-6 Antibody [NB600-1131] - GBM ECs express IL-6. Mouse GBM was induced by orthotopic injection of GL26 glioma cells into wild-type mouse. The brain sections that include normal brains and tumors were stained with anti-CD31, anti-IL-6, and anti-CSF-1 antibodies. Representative immunofluorescence images are shown. Right, enlarged area in normal and tumor tissues. Bar represents 50?um. Zoom-in factor: 4 Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-018-03050-0) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/IL-6-Antibody-Immunocytochemistry-Immunofluorescence-NB600-1131-img0015.jpg)
![Western Blot: IL-6 Antibody [NB600-1131] - Protein was resolved on a 4-20% Tris-Glycine gel by SDS-PAGE and transferred onto nitrocellulose. The blot shows detection of a band 21 kDa in size corresponding to anti-IL6 antibody. Molecular weight markers are also shown (MW). After transfer, the membrane was blocked for 30 minutes with 1% BSA-TBST. Detection occurred using peroxidase conjugated anti-Rabbit IgG secondary antibody diluted 1:40,000 in blocking buffer for 30 min at RT followed by reaction with FemtoMax chemiluminescent substrate.](http://images.novusbio.com/fullsize/IL-6-Antibody-Western-Blot-NB600-1131-img0013.jpg)
![Immunocytochemistry/ Immunofluorescence: IL-6 Antibody [NB600-1131] - GBM ECs express IL-6. a Human brain ECs were treated with glioma-CM for 24 h, & cell lysates were subjected to multiplex cytokine array analysis. Left, a representative blot. Right, quantified dot intensity of most significantly changed cytokines. b Human microvascular brain ECs were treated with glioma-CM that were harvested from different human glioma cells. Cell lysates were immunoblotted. c Human microvascular brain ECs & tumor-associated ECs isolated from different GBM patients were subjected to immunoblot analysis. d Mouse GBM was induced by orthotopic injection of GL26 glioma cells into wild-type mouse. The brain sections that include normal brains & tumors were stained with anti-CD31, anti-IL-6, & anti-CSF-1 antibodies. Representative immunofluorescence images are shown. Right, enlarged area in normal & tumor tissues. Bar represents 50 μm. Zoom-in factor: 4 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29422647), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1131_rabbit-polyclonal-il-6-antibody-310202416154648.jpg)
![N/A IL-1 beta/IL-1F2 [Biotin]](http://images.novusbio.com/fullsize2/IL1_beta_HSLB0_ELISA_1141.jpg "N/A IL-1 beta/IL-1F2 [Biotin]")
![N/A IL-1 beta/IL-1F2 [Biotin]](http://images.novusbio.com/fullsize2/DATA_IL1_beta_HSLB0_ELISA_896.jpg)
![N/A IL-1 beta/IL-1F2 [Biotin]](http://images.novusbio.com/fullsize2/IL1_beta_HSLB0_ELISA_1136.jpg)
![N/A IL-1 beta/IL-1F2 [Biotin]](http://images.novusbio.com/fullsize2/IL-1_beta_HSLB00C_ELISA_403.jpg)
![N/A IL-2 [Biotin]](http://images.novusbio.com/fullsize2/DATA_IL2_DY202_ELISA_1749.jpg "N/A IL-2 [Biotin]")
![Immunohistochemistry-Frozen: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Staining of acetone-fixed, frozen sections of pig tongue at a dilution of 1:4000](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunohistochemistry-Frozen-NB600-450-img0003.jpg "Immunohistochemistry-Frozen: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Staining of acetone-fixed, frozen sections of pig tongue at a dilution of 1:4000")
![Immunohistochemistry: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Analysis of an FFPE ligament section. Enzymatic antigen retrieval and blocking using 1% BSA for 30 min at 20C was performed. Sample was incubated for 1 hour with primary antibody at a dilution of 1:400 at 20C.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunohistochemistry-NB600-450-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Collagen I and collagen III accumulate in C57BL/6 mice in response to radiation. Bladder strips from irradiated and control mice were stained for collagen I or for collagen III (NB600-594, RRID:AB_10001330) and imaged using fluorescent microscopy. Representative images (100 x 100 um) of each mouse strain and treatment group are provided for collagen I and collagen III immunofluorescence. Image collected and cropped by CiteAb from the following publication (www.onlinelibrary.wiley.com/doi/abs/10.14814/phy2.14377) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunocytochemistry-Immunofluorescence-NB600-450-img0014.jpg)
![Immunohistochemistry: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Staining of acetone-fixed, frozen sections of human tongue at a dilution of 1:2000.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunohistochemistry-NB600-450-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Analysis of Collagen I alpha 1 in 4% PFA fixed equine tenocytes using anti-Collagen I alpha 1 antibody. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunocytochemistry-Immunofluorescence-NB600-450-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Collagen I alpha1 labeled pig trabecular meshwork cells indirectly visualized with Alexa Fluor 488 conjugated secondary antibody. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunocytochemistry-Immunofluorescence-NB600-450-img0012.jpg)
![Immunohistochemistry: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Analysis of formalin fixed frozen porcine skin tissue sections. Blocking: 5% serum for 1 hr at 20C. Sample was incubated for 16 hours at 4C and used at a dilution of 1:500.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunohistochemistry-NB600-450-img0008.jpg)
![Immunohistochemistry: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Immunohistochemistry for type I collagen in keloid (20x). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28638180/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunohistochemistry-NB600-450-img0013.jpg)
![Immunohistochemistry-Paraffin: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - Mouse healthy liver. Anibody at 1:200. Enzymatic/proteolytic antigen retrieval. No permeabilization. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Collagen-I-alpha-1-Antibody-COL-1-Immunohistochemistry-Paraffin-NB600-450-img0015.jpg)
![Immunohistochemistry: Collagen I alpha 1 Antibody (COL-1) [NB600-450] - FSP‐1–positive cells only partially responsible for collagen I & III production in irradiated bladders. Bladder strips from irradiated mice were costained for collagen I or for collagen III mRNA (pink) & for fibroblasts (FSP‐1, brown). U: urothelium; LP: lamina propria. Black arrow: FSP‐1 positive cells. Gray arrow: collagen only positive cells. Scale bar = 50 µm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32109348), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-450_mouse-monoclonal-collagen-i-alpha-1-antibody-col-1-310202415175218.jpg)
![Immunocytochemistry/Immunofluorescence: Langerin/CD207 Antibody (929F3.01) [DDX0362P-100] - Langerin Antibody (929F3.01) [DDX0362P-100] - IF staining on isolated skin-isolated porcine Langerhans cells .](http://images.novusbio.com/fullsize/Langerin-CD207-Antibody-929F3-01-Immunocytochemistry-Immunofluorescence-DDX0362P-100-img0009.jpg "Immunocytochemistry/Immunofluorescence: Langerin/CD207 Antibody (929F3.01) [DDX0362P-100] - Langerin Antibody (929F3.01) [DDX0362P-100] - IF staining on isolated skin-isolated porcine Langerhans cells .")
![Immunohistochemistry: Langerin/CD207 Antibody (929F3.01) [DDX0362P-100] - Epidermal LC are dispensable for betaGal-specific immunity but down-regulate OVA-specific T cell functions. LangDTR or B6 WT mice were injected once with 1ug DT. Epidermal sheets were stained for langerin expression 3 wks later. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0128722), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Langerin-CD207-Antibody-929F3-01-Immunohistochemistry-DDX0362P-100-img0023.jpg)
![Flow Cytometry: Langerin/CD207 Antibody (929F3.01) [DDX0362P-100] - Cells derived from culture of porcine skin stained permeabilized (D) or not (C) with 929F3](http://images.novusbio.com/fullsize/Langerin-CD207-Antibody-929F3-01-Flow-Cytometry-DDX0362P-100-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: Langerin/CD207 Antibody (929F3.01) [DDX0362P-100] - Mouse epidermal sheet.](http://images.novusbio.com/fullsize/Langerin-CD207-Antibody-929F3-01-Immunocytochemistry-Immunofluorescence-DDX0362P-100-img0008.jpg)
![Immunohistochemistry-Frozen: Langerin/CD207 Antibody (929F3.01) [DDX0362P-100] - Analysis using the HRP conjugate of DDX0362P-100. Staining of human skin frozen section.](http://images.novusbio.com/fullsize/Langerin-CD207-Antibody-929F3-01-Immunohistochemistry-Frozen-DDX0362P-100-img0020.jpg)
![Immunohistochemistry-Frozen: Langerin/CD207 Antibody (929F3.01) [DDX0362P-100] - IHC staining of human skin cryosections with 929F3-HRP](http://images.novusbio.com/fullsize/Langerin-CD207-Antibody-929F3-01-Immunohistochemistry-Frozen-DDX0362P-100-img0022.jpg)
![Flow Cytometry: Langerin/CD207 Antibody (929F3.01) [DDX0362P-100] - LC migration from the epidermis is reduced the in K14E7 mice.C57Bl/6 & K14E7 mice were painted with FITC on a 15mm2 area of abdomen & inguinal lymph nodes harvested 48 h later. Single cell suspensions were stained with CD11c, MHC class II & CD207 (A). The absolute number of FITC positive cells was determined (B). The total migrated LC in the lymph nodes as a percentage of the mean total number of LC in the painted skin is shown (C). *P < 0.05 (Mann-Whitney U test). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0127155), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/ddx0362p-100_rat-monoclonal-langerin-cd207-antibody-929f3-01-310202415175215.jpg)
![Flow Cytometry: Langerin/CD207 Antibody (929F3.01) [DDX0362P-100] - Antigen uptake is reduced in K14E7 mice.Epidermal cell suspensions from C57BL/6 & K14E7 mice were cultured with Alexa-555-labelled OVA overnight at 37°C, stained & analysed by flow cytometry (A). The Alexa-555-OVA+ LC (CD45.2+, MHC Class II+, CD207+) as a percentage of total LC (B) & the level of expression of Alexa-555-OVA on the positive stained LC is shown (C). **P < 0.01; *P < 0.05 (Mann-Whitney U test). Confocal imaging of CD207+, MHCII+ LC that have taken up Alexa-555-OVA (D). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0127155), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/ddx0362p-100_rat-monoclonal-langerin-cd207-antibody-929f3-01-31020241535681.jpg)
![Immunocytochemistry/ Immunofluorescence: Langerin/CD207 Antibody (929F3.01) [DDX0362P-100] - Antigen uptake is reduced in K14E7 mice.Epidermal cell suspensions from C57BL/6 & K14E7 mice were cultured with Alexa-555-labelled OVA overnight at 37°C, stained & analysed by flow cytometry (A). The Alexa-555-OVA+ LC (CD45.2+, MHC Class II+, CD207+) as a percentage of total LC (B) & the level of expression of Alexa-555-OVA on the positive stained LC is shown (C). **P < 0.01; *P < 0.05 (Mann-Whitney U test). Confocal imaging of CD207+, MHCII+ LC that have taken up Alexa-555-OVA (D). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0127155), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/ddx0362p-100_rat-monoclonal-langerin-cd207-antibody-929f3-01-310202415304274.jpg)
![Immunohistochemistry: Langerin/CD207 Antibody (929F3.01) [DDX0362P-100] - The absolute number of LC is increased in K14E7 mouse epidermis.Sections of C57Bl/6 (A) & K14E7 (B) mouse ear were stained with CD207 & imaged by epifluorescence microscopy. The epidermis (top) is indicated by a broad dashed line, & the epidermis/dermis interface by a narrow dashed line; scale bar = 50μm. LC (CD45.2, CD11c, CD207, MHCII+) harvested from a 5.5 mm diameter sample of dorsal ear epidermis were enumerated, with counting beads, by flow cytometry. The absolute number (C) & the percentage of LC (D) are shown. Confocal imaging was carried out on CD207-stained sheets of dorsal ear skin (E). Scale bar represents 20μm. Dendrites on the CD207+ LC were enumerated following confocal imaging (F). **P < 0.01 (Mann-Whitney U test). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0127155), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/ddx0362p-100_rat-monoclonal-langerin-cd207-antibody-929f3-01-310202415482235.jpg)
![Immunocytochemistry/ Immunofluorescence: Langerin/CD207 Antibody (929F3.01) [DDX0362P-100] - The absolute number of LC is increased in K14E7 mouse epidermis.Sections of C57Bl/6 (A) & K14E7 (B) mouse ear were stained with CD207 & imaged by epifluorescence microscopy. The epidermis (top) is indicated by a broad dashed line, & the epidermis/dermis interface by a narrow dashed line; scale bar = 50μm. LC (CD45.2, CD11c, CD207, MHCII+) harvested from a 5.5 mm diameter sample of dorsal ear epidermis were enumerated, with counting beads, by flow cytometry. The absolute number (C) & the percentage of LC (D) are shown. Confocal imaging was carried out on CD207-stained sheets of dorsal ear skin (E). Scale bar represents 20μm. Dendrites on the CD207+ LC were enumerated following confocal imaging (F). **P < 0.01 (Mann-Whitney U test). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0127155), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/ddx0362p-100_rat-monoclonal-langerin-cd207-antibody-929f3-01-310202415483613.jpg)
![Immunocytochemistry/ Immunofluorescence: Langerin/CD207 Antibody (929F3.01) [DDX0362P-100] - The absolute number of LC is increased in K14E7 mouse epidermis.Sections of C57Bl/6 (A) & K14E7 (B) mouse ear were stained with CD207 & imaged by epifluorescence microscopy. The epidermis (top) is indicated by a broad dashed line, & the epidermis/dermis interface by a narrow dashed line; scale bar = 50μm. LC (CD45.2, CD11c, CD207, MHCII+) harvested from a 5.5 mm diameter sample of dorsal ear epidermis were enumerated, with counting beads, by flow cytometry. The absolute number (C) & the percentage of LC (D) are shown. Confocal imaging was carried out on CD207-stained sheets of dorsal ear skin (E). Scale bar represents 20μm. Dendrites on the CD207+ LC were enumerated following confocal imaging (F). **P < 0.01 (Mann-Whitney U test). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0127155), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/ddx0362p-100_rat-monoclonal-langerin-cd207-antibody-929f3-01-310202415482259.jpg)
